Brief: Eurocine Vaccines Has Selected Biovian As Contract Developer For The Chlamydia Vaccine Candidate
Dec 30 (Reuters) - Eurocine Vaccines AB EUCI.TE :
* EUROCINE VACCINES HAS SELECTED BIOVIAN AS CONTRACT
DEVELOPER FOR
THE CHLAMYDIA VACCINE CANDIDATE
* COLLABORATION SIGNED TODAY WITH BIOVIAN COVERS ACTIVITIES
INITIALLY LASTING UNTIL NOVEMBER 2021
* AGREEMENT SIGNED TODAY INCLUDES ACTIVITIES AT A TOTAL COST
OF
APPR. SEK 9.5 MILLION (EUR 0.94 MILLION)
Source text for Eikon: ID:nWkr1bNBlk
Further company coverage: EUCI.TE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nidhogg Resources Holding AB (publ)
See all newsBrief: Nidhogg Resources Holding Resolves On A Directed Set-Off Share Issue
Brief: Nidhogg Resources Holding AB Announces The Termination Of The Al Baraka Project In Egypt
Brief: Eurocine Vaccines Q4 EPS at SEK -0.111
Brief: Eurocine Vaccines Says Decides To Develop mRNA-Based Vaccine Candidate Against Chlamydia
Brief: Eurocine Vaccines Expands Its Portfolio With A Therapeutic Hsv-2 Vaccine Candidate